Bone Metabolism Clinical Trial
Official title:
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Pioglitazone Compared to Placebo on Bone Metabolism in Impaired Fasting Glucose, Postmenopausal Women for One Year of Treatment
The purpose of this study is to evaluate the effect of pioglitazone on bone metabolism in postmenopausal women with impaired fasting glucose.
The World Health Organization has estimated that 30% of all women aged over 50 years
(postmenopausal) have osteoporosis according to a definition of Bone Mineral Density at any
site being more than 2.5 standard deviations below the mean for young healthy adult women.
A known risk factor for development of osteoporosis and fracture is diabetes mellitus, with
correlations to duration of disease and poor glycemic control.
Pioglitazone is a thiazolidinedione developed by Takeda Pharmaceuticals for the treatment of
type 2 diabetes. Preclinical studies to date on the bone effects of thiazolidinediones have
not clearly identified a mechanism of bone loss. While there is evidence of increased bone
fractures in postmenopausal diabetic females treated with a thiazolidinedione, the mechanism
is not known. Initial studies with thiazolidinediones in humans have focused on short term
exposure (12 to 14 weeks) and non-diabetic females. These studies have shown acute changes
in circulating bone markers and bone density, but have been questioned because they may not
represent bone metabolism in states of abnormal glucose metabolism. Impaired glucose
tolerance has been identified not only as a risk factor for developing type 2 diabetes, but
also at higher risk for known complications of diabetes. Examination of the effect of
thiazolidinediones on bone metabolism in IGT patients will provide data in patients with
abnormal glucose tolerance, but without the potential confounding effects of oral
hypoglycemic medications to treat type 2 diabetes.
The primary objective of this study is to evaluate the effect of pioglitazone on bone mass
and metabolism in postmenopausal women with impaired fasting glucose or impaired glucose
tolerance. Total participation time in this study is approximately 1 year and six months.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00973336 -
Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery?
|
Phase 2 | |
Completed |
NCT04203212 -
BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH
|
||
Not yet recruiting |
NCT06182852 -
The Effect of GLP-1 Receptor Agonist on Bone Metabolism in Patients With Diabetes Mellitus
|
||
Completed |
NCT01773304 -
Acute Effects of Dairy and Meat Proteins on Bone Metabolism and Metabolic Profile
|
N/A | |
Withdrawn |
NCT00853502 -
The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa
|
Phase 2 | |
Completed |
NCT01183299 -
Salty Life 7 Study: Effect of High Salt Intake on Several Physiological Systems in Immobilisation
|
N/A |